News from IsoPlexis Corporation A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Dec 14, 2017, 09:00 ET UCLA and Caltech Study Uses Technology Being Commercialized by IsoPlexis To Characterize Cancer Cells Resistant to Targeted Treatments

Researchers from Caltech and UCLA used novel single-cell phosphoproteomic detection technologies, currently being commercialized by...


Dec 11, 2017, 09:02 ET IsoPlexis Wins 2017 Fierce Technology Innovation Award

IsoPlexis Corporation (IsoPlexis), a privately held life sciences company at the forefront of single-cell analytics technology and the immune-based...


Dec 04, 2017, 09:00 ET IsoPlexis To Present New Collaboration Data at the American Society of Hematology Annual Meeting

IsoPlexis Corporation (IsoPlexis), a privately held life science company at the forefront of single-cell analytics technology and the immune-based...


Dec 01, 2017, 08:00 ET The Scientist Names IsoPlexis Technology The Top Innovation of 2017

IsoPlexis Corporation (IsoPlexis), a privately held life sciences company at the forefront of single-cell analytics technology and the immune-based...


Nov 21, 2017, 09:06 ET Journal for ImmunoTherapy of Cancer Highlights New Single Cell Bioinformatics Tools From IsoPlexis Used To Characterize Differences in CAR-T Products

IsoCode, IsoPlexis Corporation's (IsoPlexis') single-cell precision platform, captured novel data from CAR-T products developed by Novartis...


Oct 23, 2017, 09:00 ET IsoPlexis Receives $1.8M National Cancer Institute Grant To Develop Automated Platform To Assess CAR-T Product Potency and Toxicity and Predict Patient Response

IsoPlexis Corporation (IsoPlexis), a privately held life sciences company at the forefront of single-cell analytics technology and the immune-based...


Sep 25, 2017, 09:00 ET IsoPlexis Raises $13.5 Million in Series B Financing

IsoPlexis Corporation (IsoPlexis), a privately held life science company at the forefront of single-cell analytics technology and the immune-based...


Apr 03, 2017, 16:05 ET IsoPlexis Collaboration Offers Breakthrough Insights into Detecting and Predicting Patient Response to T-Cell Therapy

Data captured by IsoCode, IsoPlexis Corporation's (IsoPlexis) single-cell precision engineering platform, detected a statistically significant...


Mar 14, 2017, 08:00 ET IsoPlexis Adds Infectious Disease Pioneer Dr. David Ho to its Scientific Advisory Board

IsoPlexis Corporation (IsoPlexis), a venture capital-funded life sciences company dedicated to accelerating the fight against cancer, autoimmune...